MVision AI

Koti
Suomi
Helsinki
MVision AI

Yhteystiedot, kartta ja reittiohjeet, yhteydenottolomake, aukioloajat, palvelut, arvostelut, kuvat, videot ja ilmoitukset MVision AI, Terveys, PaciuksenKatu 29, Helsinki :ltä.

MVision develops AI-powered solutions that automate repetitive tasks, enable efficient radiotherapy workflows, and promote consistency across clinical processes.

10/03/2026

MVision AI will take part in the 39th Annual Meeting of the Japan High Precision External Beam Radiotherapy Group / Japanese Society for Radiation Oncology on March 14, 2026 in Tokyo at the Ochanomizu Sola City Conference Center.

MVision Founder & CEO Mahmudul Hasan will attend the meeting with our partner ITEM Corporation, and will also participate in a joint presentation:

🧠 AI-Assisted Radiation Therapy Treatment Preparation
📅 March 14 | 15:30–16:30

We value the opportunity to exchange perspectives with the Japanese radiotherapy community and contribute to ongoing discussions on how AI can support clinical decision-making and treatment planning.

*The technologies featured in this seminar have not yet received regulatory approval and are currently not available for sale in Japan. For more information, please contact info@mvision.ai or info@item-corp.jp.

03/03/2026

MVision AI is one of the sponsors of the ISROI Meeting 2026 in St. Gallen, Switzerland on March 6, focused on the latest developments in Radiation Oncology Informatics.

ISROI brings together experts from across Europe to explore data science, IT security, AI, foundation models, system integration, and workflow optimization in radiation oncology.

We’re pleased to support this event dedicated to addressing practical challenges and advancing technical innovation in radiation oncology informatics.

27/02/2026

In our latest ‘Expert Perspectives: AI in Radiotherapy’ interview, we speak with Michael Roche, Principal Physicist in Radiotherapy at the CUH/UCC Cancer Centre in Cork University Hospital.

Michael shares how AI-driven contouring has been safely integrated into a busy clinical workflow, what measurable impact it’s had on CT-to-treatment timelines, and why strong governance is essential as AI becomes more embedded in radiotherapy services.

This interview offers a clear, real-world view of how AI can support efficiency, consistency, and staff wellbeing—without replacing clinical judgement.

Read the full interview here:
https://bit.ly/4l1f7HC

25/02/2026

Cancer in the US continues to place growing pressure on patients, clinicians, and healthcare systems.

In our updated review of the landscape, we look at how cancer care and radiotherapy are evolving, from access and cost to the role of telemedicine and AI in treatment planning.

Where is progress being made? And where do gaps remain, especially for patients who live far from treatment centers or face financial barriers?

Read the full article for a data-driven overview of current trends in US oncology: https://bit.ly/3MtZn3f

20/02/2026

We were pleased to see independent research featuring MVision AI presented at the 2026 BIR Annual Radiotherapy and Oncology Meeting in London.

The poster, created by researchers from Mid and South Essex NHS Foundation Trust, evaluated the dosimetric impact of using MVision AI for head and neck radiotherapy planning.

The team compared AI-generated contours with expert manual delineations, focusing on dose metrics for organs at risk. The authors report strong dosimetric agreement between AI and manual contours, with results that were both statistically and clinically comparable. No clinical tolerance thresholds were exceeded, and dose constraints were maintained.

The study also highlights the importance of clinical review in complex regions, while showing that AI-supported contouring can be a reliable and practical part of modern radiotherapy workflows.

Independent clinical evaluation is essential for building trust in medical AI. Studies like this support responsible adoption and help ensure that advanced technology translates into safe, high-quality care for patients.

19/02/2026

We have published a new case study describing work carried out at The Royal Marsden and The Institute of Cancer Research, exploring a simulation-free workflow for Elekta Unity MRI-guided adaptive prostate radiotherapy.

The study examines whether diagnostic MRI can be used to support reference plan generation, reducing the need for a dedicated radiotherapy simulation scan. Using clinical patient data, the team assessed whether plans generated from diagnostic MRI could achieve the same standard as those created using conventional simulation-based workflows.

The results show that the simulation-free adapted plans were equivalent to the clinical plans, met all mandatory clinical goals, and maintained plan quality and organ-at-risk sparing. This suggests a potential route to streamlining treatment preparation while maintaining high clinical standards.

The full case study describes the workflow, validation steps, and what this approach could mean for the future of MR-guided radiotherapy.

Read the case study here: https://bit.ly/4tGYMvw

A PDF version is also available to download.

17/02/2026

Another important milestone reached: Workspace+ has received market approval from the TGA in Australia. This approval allows the Workspace+ platform to be used for clinical care across Australia.

Workspace+ brings contouring, synthetic imaging, dose prediction, and contour propagation into one secure environment. Clinics can adopt modules individually or as a unified suite. The platform supports consistent planning while helping reduce manual effort and leaving clinicians in full control.

Read the full press release: https://bit.ly/4rPei6U

We remain committed to supporting radiotherapy teams across Australia with clinically grounded AI solutions.

*CE-marked (CE 2797) medical device under EU MDR 2017/745; this product is not available in all markets.

11/02/2026

MVision AI will take part in the Moffitt Radiation Oncology Conference (ROC) on February 12–14 in Tampa, Florida. The event brings together leaders in radiation oncology to explore advances in adaptive therapy, AI-enabled planning, and precision cancer care.

We’re excited to have our VP of Sales USA, Martin Clay, and Director of Product Marketing & Revenue (Americas), Melody Blake, representing MVision AI at the conference. Our team looks forward to engaging with clinicians and industry peers to share insights on how technology can support innovation and improved patient outcomes.

See you in Tampa!

09/02/2026

AMSTRO 2026 wrapped up yesterday after an inspiring and energizing few days.

Thank you to everyone who visited us at Booth #2, shared insights, and took time to discuss the future of radiotherapy. We also appreciate the strong engagement around the Industry Executive Panel, where our Founder and CEO, Mahmudul Hasan, joined the conversation on building sustainable cancer systems.

These exchanges matter. They help shape how AI can support clinicians and patients with greater consistency and confidence.

We look forward to building on these conversations in the future.

08/02/2026

The British Institute of Radiology's (BIR) Annual Radiotherapy and Oncology Meeting returns to London on February 12–13 at The Minster Building in London’s financial district.

The meeting brings the radiotherapy community together to explore advances in clinical practice, technology adoption, and patient-centred care.

MVision will be there with our distribution partner Xiel Ltd. at table 17 throughout the event.

On Thursday, February 12 at 10:30, MVisionary Hassan Hassan will present in the Minster Forum, introducing Workspace+ and outlining how its modular AI components integrate to support radiotherapy treatment preparation and clinical workflows.'

If you’re attending BIR 2026, we’d love to connect.

*Workspace+ is a CE-marked (CE 2797) medical device under EU MDR 2017/745; it is not available in all markets.

05/02/2026

An important discussion on the future of cancer systems is coming to AMSTRO 2026, and we’re glad to be part of it.

Our Founder and CEO, Mahmudul Hasan, will be joining an Industry Executive panel at AMSTRO 2026 titled “From Innovation to Impact: Industry’s Role in Building Sustainable Cancer Systems.”

It will take place on February 7 from 9:50–10:20 AM at the Zayed University Convention Center in Dubai and will be hosted by Dr. Saiful Huq. The session will bring together senior voices from across the oncology and medical technology landscape to explore how industry can help shape more sustainable, effective cancer care worldwide.

If you are attending AMSTRO 2026, in person or online, this is a conversation not to miss.

04/02/2026

Today is World Cancer Day, a time to reflect on the people, progress, and collaboration shaping the future of cancer care.

The World Cancer Day theme, “United by Unique,” highlights the reality that every cancer journey is different, while meaningful progress depends on collective effort across patients, clinicians, and the wider healthcare community.

At MVision AI, we support this mission by contributing AI-driven solutions that assist radiotherapy teams in treatment planning preparation, helping improve consistency and efficiency across clinical workflows. In doing so, we support clinicians as they work toward improved outcomes for patients.

Today, we stand with the global cancer community in advancing more effective and collaborative approaches to care.

Osoite

PaciuksenKatu 29
Helsinki
00270

Nettisivu

http://www.mvision.ai/

Hälytykset

Tiedä ensimmäisenä ja anna meille oikeus lähettää sinulle sähköpostitse uutisia ja promootioita MVision AI :ltä. Sähköpostiosoitettasi ei käytetä muihin tarkoituksiin, ja voit perua milloin tahansa.

Oma vastaanotto listan huipulle Klinikka Helsinki :ssa?

Jaa

Kategoria

Terveys